Precision Genomic Testing Market Report 2026

Precision Genomic Testing Market Overview

• Precision Genomic Testing market size has reached to $15 billion in 2025 • Expected to grow to $25.71 billion in 2030 at a compound annual growth rate (CAGR) of 11.3% • Growth Driver: The Rise In Genetic Disorders Propelling The Growth Of The Market Due To Increasing Maternal Age And Demand For Early Diagnosis • Market Trend: Breakthrough In Early Cancer Detection With Ultra-Sensitive DNA Assays • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Precision Genomic Testing Market?

Precision genomic testing refers to the use of advanced genetic analysis to identify specific variations or mutations in a person’s DNA that can influence disease risk, diagnosis, prognosis, or response to treatment. It enables personalized healthcare by tailoring prevention strategies, therapies, and drug choices to an individual’s unique genetic makeup. The main products and services of precision genomic testing are consumables, equipment, and services. Consumables refer to items that are intended to be used up or depleted through regular use, such as laboratory reagents, printer ink, or medical supplies. This testing leverages a range of advanced technologies such as next-generation sequencing, polymerase chain reaction, microarray technology, Sanger sequencing, clustered regularly interspaced short palindromic repeats or clustered regularly interspaced short palindromic repeats-associated systems, and others. These are used in various applications such as oncology, cardiovascular diseases, neurological disorders, reproductive health, rare diseases, and others, and cater to end-users such as hospitals and clinics, diagnostic laboratories, research and academic institutes, and others.

What Is The Precision Genomic Testing Market Growth Forecast?

The precision genomic testing market size is expected to see rapid growth in the next few years. It will grow to $25.71 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to increasing adoption of precision medicine, rising investments in genomic research, expansion of population-scale genomic initiatives, growing demand for companion diagnostics, increasing integration of genomics into routine clinical practice. Major trends in the forecast period include increasing adoption of next-generation sequencing, rising use of AI-based genomic interpretation, growing demand for personalized treatment planning, expansion of clinical genomic testing, enhanced integration of bioinformatics platforms.

Global Precision Genomic Testing Market Segmentation

1) By Product And Service: Consumables, Equipment, Services 2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Microarray Technology, Sanger Sequencing, Clustered Regularly Interspaced Short Palindromic Repeats Or Clustered Regularly Interspaced Short Palindromic Repeats-Associated Systems, Other Technologies 3) By Application: Oncology, Cardiovascular Diseases, Neurological Disorders, Reproductive Health, Rare Diseases, Other Applications 4) By End-Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End-Users Subsegments: 1) By Consumables: Reagents And Kits, Deoxyribonucleic Acid Or Ribonucleic Acid Extraction Kits, Library Preparation Kits, Sequencing Reagents, Polymerase Chain Reaction Assay Kits, Buffers And Enzymes 2) By Equipment: Next-Generation Sequencing Systems, Polymerase Chain Reaction Machines, Microarray Instruments, Deoxyribonucleic Acid Analyzers, Bioinformatics Workstations, Laboratory Automation Systems 3) By Services: Genomic Data Analysis Services, Laboratory Testing Services, Genetic Counseling Services, Clinical Interpretation Services, Contract Research Services, Custom Assay Development Services

What Is The Driver Of The Precision Genomic Testing Market?

The rising prevalence of genetic disorders is expected to propel the growth of the precision genomic testing market going forward. Genetic disorders refer to medical conditions caused by abnormalities in an individual's DNA, such as mutations in a single gene, multiple genes, or changes in chromosome structure or number. The growing prevalence of genetic disorders is primarily due to increasing maternal age, as older mothers have a higher risk of passing chromosomal abnormalities, such as down syndrome, to their children. Precision genomic testing enables the early detection and accurate diagnosis of genetic disorders by identifying specific genetic mutations, allowing for targeted interventions and personalized treatment strategies. For instance, in May 2025, Gene People, a UK-based registered charity, stated that genetic conditions affect an estimated 1 in 25 children, impacting over 2.4 million children and adults in the UK. Additionally, around 30,000 newborns and children in the UK are diagnosed with a genetic condition each year. Therefore, the rising prevalence of genetic disorders is driving the growth of the precision genomic testing industry.

Key Players In The Global Precision Genomic Testing Market

Major companies operating in the precision genomic testing market are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Exact Sciences Corporation, Natera Inc., Myriad Genetics Inc., GenScript Biotech Corporation, Fulgent Genetics Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Ambry Genetics Corporation, Color Health Inc., Pacific Biosciences, Eurofins Genomics LLC, BGI Genomics Co. Ltd.

Global Precision Genomic Testing Market Trends and Insights

Major companies operating in the precision genomic testing market are focusing on developing innovative solutions, such as ultra-sensitive circulating tumor deoxyribonucleic acid assays, to enable earlier and more accurate detection of cancer. Ultra-sensitive circulating tumor deoxyribonucleic acid assays are advanced tests that detect tiny fragments of tumor-derived deoxyribonucleic acid in the blood, enabling early and precise identification of cancer-related genetic mutations. For instance, in April 2025, Natera Inc., a US-based clinical genetic testing company, launched the ultra-sensitive Signatera genome molecular residual disease test. This test utilizes whole genome sequencing of both a patient's tumor and matched normal deoxyribonucleic acid to create a personalized assay, enabling the detection of circulating tumor deoxyribonucleic acid at extremely low levels, down to 1 part per million. This high level of sensitivity supports earlier and more precise detection of cancer recurrence, ultimately enhancing treatment planning and patient management across various cancer types.

What Are Latest Mergers And Acquisitions In The Precision Genomic Testing Market?

In May 2025, QIAGEN N.V., a Netherlands-based life sciences and molecular diagnostics company, acquired Genoox Ltd., for an undisclosed amount. With this acquisition, QIAGEN N.V. aims to strengthen its clinical genomics portfolio by integrating Genoox’s artificial intelligence–driven platform for variant interpretation, enabling faster, more accurate genomic insights for hereditary disease, oncology, and other clinical applications. Genoox Ltd. is an Israel-based genomics technology company that specializes in cloud-based AI tools for analyzing, interpreting, and sharing genomic data across clinical and research settings.

Regional Outlook

North America was the largest region in the precision genomic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Precision Genomic Testing Market?

The precision genomic testing market consists of revenues earned by entities by providing services such as gene panel testing, whole genome and exome analysis, pharmacogenomics testing, cancer genomics profiling, hereditary disease screening, and bioinformatics-driven interpretation of genetic data. The market value includes the value of related goods sold by the service provider or included within the service offering. The precision genomic testing market also includes sales of hybridization buffers and enzymes, targeted gene panels, library preparation kits, genomic data compression tools, and rare mutation detection kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Precision Genomic Testing Market Report 2026?

The precision genomic testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the precision genomic testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.